Webcast: Biosimilars: Friend or Foe to Healthcare?
Understanding the opportunities for biosimilars and the threats to innovator biologics
Referencing recent findings from our Therapy Watch syndicated study in RA, this webinar investigates physicians' perceptions of the biosimilars market. Therapy Watch Director Allison Fleetwood and Access Partnership Director Shrinivas Rao Mukku interview a major US payer, who offers expert opinion on the opportunities for biosimilars in the US market, the possible threats to originator brands, and consider what companies entering the market need to do to effectively launch their follow-on biologic.
Biosimilars: Friend or Foe?
Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.
Announcing a new strategic market access consultancy
The Research Partnership is today launching a new market access consultancy called "The Access Partnership" which will provide services to the pharmaceutical, biotech and medtech industries.
The Access Partnership will work with manufacturers to help them develop the value strategy for their technologies, including pricing, market access and payer engagement, in order to achieve commercial success for their innovations. The company’s global headquarters are based in London, UK, with other offices in the US and Singapore.The company has also made two senior appointments. Rob White joins as Global Director of Market Access and Dr Shrinivas Rao Mukku joins as Global Director of Pricing and Reimbursement.Rob White (shown above) has over 20 years experience within the pharma industry at Sanofi Aventis and MSD leading on a number of roles including delivering market access strategies and tools to support brands in key areas such as diabetes, HIV, oncology, cardiovascular as well as the device space. Rob has developed an extensive payer network which he has used to help clients deliver relevant payer value propositions and support segmentation across the EU and US markets. Rob has also delivered training for pharma KAM teams and supported teams with contract negotiations and the development of business cases to drive brand market access.Shrinivas Rao Mukku has 18 years of research management, training and consultancy experience in Europe and South East Asia. In…